TGA Approves XTANDI for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

The TGA has approved XTANDI® (enzalutamide) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).

Access the Media Release: The Therapeutic Goods Administration (TGA) of Australia approves XTANDI® (enzalutamide) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer.